Skip to content

Evaluating the Safety and Effectiveness of a Hair Care Product for Reducing Grey Hair in Healthy People

The objective of this study will be to evaluate the invivo safety and efficacy of a hair care formulation in terms of reduction in grey hair on healthy human subject - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075870
Enrollment
36
Registered
2024-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dermina greygone - antigreying hair serum: Product to be applied on whole scalp and shafts, two times in a day for the period of 84 days. Control Intervention1: Nil: NA

Sponsors

Curetech Skincare
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Indian / Asian male & female subjects. 2) Healthy subjects 3) Skin is healthy on the studied anatomic unit 4) Subjects with non-congenital factors contributing to premature graying, such as stress, dietary habits, or environmental exposure & those with congenital factors may also be included, 5) Having a mild to moderate greying severity score in a one-to-one ratio.

Exclusion criteria

Exclusion criteria: 1. For Females: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2. Having refused to give his/her assent by not signing the consent form 3. Taking part in another study liable to interfere with this study 4. Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area 5. Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months) 6. Having a progressive asthma (either under treatment or last fit in the last 2 years) 7. Being epileptic 8. Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 9. Having cutaneous hypersensitivity 10. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products 11. Following a chronic or intermittent medicinal treatment comprising any of the following products:aspirin-based products, anti-inflammatories, antihistamines, anti-coagulants, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 12. Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months

Design outcomes

Primary

MeasureTime frame
Reduction in grey hairTimepoint: Baseline, Day 28, Day 56 and Day 84

Secondary

MeasureTime frame
NilTimepoint: NA

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

poojayadav@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026